BCMA-expression profiles of plasma cells. (A-B) BCMA expression measured as a percentage of total plasma cell BCMA expression comparing (A) teclistamab nonresponders and responders and (B) patients with and without prior anti-BCMA exposure. (C-D) Plasma cell BCMA expression measured by BCMA staining intensity by IHC (scale, 0-3) comparing (C) teclistamab nonresponders with responders, and (D) patients with and without prior anti-BCMA exposure. (E-F) Pretreatment bone marrow biopsies showing positive BCMA staining (brown) by IHC for representative patients including (E) a patient refractory to both belantamab mafodotin and idecabtagene-vicleucel but responding to teclistamab, and (F) a patient who achieved MRD-CR after idecabtagene-vicleucel now responding to teclistamab after relapse. CR, complete response; MRD, minimal residual disease.